Evidence map›Paper›PMID 37468728›Full record

ReviewMammalian genome : official journal of the International Mammalian Genome Society2023

INFRAFRONTIER: mouse model resources for modelling human diseases.

Asrar Ali Khan, Gema Valera Vazquez, Montse Gustems, Rafaele Matteoni, Fei Song, Philipp Gormanns, Sabine Fessele, Michael Raess, Martin Hrabĕ de Angelis, INFRAFRONTIER Consortium

Abstract readReview
In one paragraph

Review in Mammalian genome : official journal of the International Mammalian Genome Society, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. A quality framework for cryopreserved rodent disease models: INFRAFRONTIER quality principles in EMMA archiving and distribution.Mammalian genome : official journal of the International Mammalian Genome Society · 2025
    Review
  6. Article
  7. Article
  8. Commentary: The International Mouse Phenotyping Consortium: high-throughput in vivo functional annotation of the mammalian genome.Mammalian genome : official journal of the International Mammalian Genome Society · 2024
    Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Asrar Ali KhanINFRAFRONTIER GmbH, Neuherberg, Germany. asrar.khan@infrafrontier.eu.ORCID 0000-0001-7796-4957
Gema Valera VazquezINFRAFRONTIER GmbH, Neuherberg, Germany.ORCID 0000-0001-5411-7560
Montse GustemsINFRAFRONTIER GmbH, Neuherberg, Germany.ORCID 0000-0003-4447-0031
Rafaele MatteoniInstitute of Biochemistry and Cell Biology, Italian National Research Council (CNR), Monterotondo, Rome, Italy.ORCID 0000-0002-0314-5948
Fei SongINFRAFRONTIER GmbH, Neuherberg, Germany.ORCID 0009-0007-2626-7925
Philipp GormannsINFRAFRONTIER GmbH, Neuherberg, Germany.
Sabine FesseleINFRAFRONTIER GmbH, Neuherberg, Germany.ORCID 0000-0002-5399-3574
Michael RaessINFRAFRONTIER GmbH, Neuherberg, Germany.ORCID 0000-0002-8759-1186
Martin Hrabĕ de AngelisINFRAFRONTIER GmbH, Neuherberg, Germany.ORCID 0000-0002-7898-2353
INFRAFRONTIER Consortium

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Over the last decade, INFRAFRONTIER has positioned itself as a world-class Research Infrastructure for the generation, phenotyping, archiving, and distribution of mouse models in Europe. The INFRAFRONTIER network consists of 22 partners from 15 countries, and is continuously enhancing and broadening its portfolio of resources and services that are offered to the research community on a non-profit basis. By bringing together European rodent model expertise and providing valuable disease model services to the biomedical research community, INFRAFRONTIER strives to push the accessibility of cutting-edge human disease modelling technologies across the European research landscape. This article highlights the latest INFRAFRONTIER developments and informs the research community about its extensively utilised services, resources, and technical developments, specifically the intricacies of the INFRAFRONTIER database, use of Curated Disease Models, overview of the INFRAFRONTIER Cancer and Rare Disease resources, and information about its main state-of-the-art services.

Indexed as

Biomedical ResearchAnimalsDisease Models, AnimalEuropeHumansMice

Identifiers

PMID37468728
PMCPMC10382402

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.